Valneva SE (VALN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

7/25

Growth 0 Margin 0 Expansion 3 Platform 2 Financial 2

latest quarter score

Earnings Reports

7
Valneva (VALN) H1 2026: €40M Adjusted EBITDA Loss Highlights Restructuring and Product Transition Challenges
August 18, 2026
9
Valneva (VALN) Q1 2026: OPEX Slashed 25–35% as Lyme Uncertainty Forces Restructuring
May 13, 2026
12
Valneva (VALN) FY 2025: Proprietary Product Sales Up 9% as Lyme Vaccine Nears Phase 3 Readout
March 18, 2026
13
Valneva (VALN) Q3 2025: 12.5% Ixiaro Growth Offsets Chikungunya Setback, Lyme Catalyst Looms
November 23, 2025
16
Valneva (VALN) Q2 2025: Product Sales Jump 33% as Lyme Vaccine Milestone Nears
August 12, 2025
11
Valneva (VALN) Q1 2025: Product Sales Surge 51%, Lyme Vaccine Data Looms as Profitability Pivot
July 07, 2025

Browse all companies